Salivary proteomics and biomarkers in neurology and psychiatry

Proteomics - Clinical Applications

Volumn 9, Issue 9-10, 2015, Pages 899-906

  Wormwood, Kelly L ^a   Aslebagh, Roshanak ^a   Channaveerappa, Devika ^a   Dupree, Emmalyn J ^a   Borland, Megan M ^a   Ryan, Jeanne P ^b   Darie, Costel C ^a   Woods, Alisa G ^a,b  

^a CLARKSON UNIVERSITY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Biomarkers; Proteomics

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ALPHA CRYSTALLIN; ALPHA SYNUCLEIN; AMYLASE; AMYLOID BETA PROTEIN[1-42]; ANDROGEN; CALGRANULIN; CALNEXIN; CYCLOPHILIN A; CYSTATIN; CYTOKINE; DESVENLAFAXINE; DJ 1 PROTEIN; HEAT SHOCK PROTEIN 90 ALPHA; HISTATIN; HYDROCORTISONE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LACTOFERRIN; LEUKOCYTE ELASTASE; OXYTOCIN; PROLINE RICH PROTEIN; SECRETORY COMPONENT; SEROTONIN UPTAKE INHIBITOR; STATHERIN; TAU PROTEIN; TRANSALDOLASE; VALOSIN CONTAINING PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AUTISM; AUTOPSY; BLOOD ANALYSIS; BRAIN TISSUE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITION; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DRUG RESPONSE; FIBROMYALGIA; HEROIN DEPENDENCE; HUMAN; MAJOR DEPRESSION; MASS SPECTROMETRY; MENTAL DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SALIVA ANALYSIS; SALIVA LEVEL; SUICIDE; METABOLISM; NEUROLOGY; PROCEDURES; PSYCHIATRY; SALIVA;

BIOMARKERS; HUMANS; NEUROLOGY; PROTEOMICS; PSYCHIATRY; SALIVA;

EID: 84942938997     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201400153     Document Type: Review

References (85)

1. Darie, C. C., Biniossek, M. L., Gawinowicz, M. A., Milgrom, Y. et al., Mass spectrometric evidence that proteolytic processing of rainbow trout egg vitelline envelope proteins takes place on the egg. J. Biol. Chem. 2005, 280, 37585-37598.
2. Darie, C. C., Deinhardt, K., Zhang, G., Cardasis, H. S. et al., Identifying transient protein-protein interactions in EphB2 signaling by blue native PAGE and mass spectrometry. Proteomics 2011, 11, 4514-4528.
3. Ngounou Wetie, A. G., Sokolowska, I., Woods, A. G., Roy, U. et al., Protein-protein interactions: switch from classical methods to proteomics and bioinformatics-based approaches. Cell. Mol. Life Sci. 2014, 71, 205-228.
4. Ngounou Wetie, A. G., Sokolowska, I., Woods, A. G., Roy, U. et al., Investigation of stable and transient protein-protein interactions: past, present, and future. Proteomics 2013, 13, 538-557.
5. Ngounou Wetie, A. G., Wormwood, K., Thome, J., Dudley, E. et al., A pilot proteomic study of protein markers in autism spectrum disorder. Electrophoresis 2014, 35, 2046-2054.
6. Sokolowska, I., Woods, A. G., Wagner, J., Dorler, J. et al., Mass spectrometry for proteomics-based investigation of oxidative stress and heat shock proteins, in: Andreescu, S., Hepel, M. (Eds.), Oxidative Stress: Diagnostics, Prevention, and Therapy, American Chemical Society, Washington D.C. 2011, pp. 369-411.
7. Taurines, R., Dudley, E., Grassl, J., Warnke, A. et al., Proteomic research in psychiatry. J. Psychopharmacol. 2011, 25, 151-196.
8. Woods, A. G., Sokolowska, I., Taurines, R., Gerlach, M. et al., Potential biomarkers in psychiatry: focus on the cholesterol system. J. Cell. Mol. Med. 2012, 16, 1184-1195.
9. Wormwood, K., Sokolowska, I., Ryan, J. P., Russell, S. et al., The potential for proteomics in understanding neurodevelopmental disorders. J. Proteomics Bioinform. 2013, S5, 1-8.
10. Woods, A. G., Sokolowska, I., Wetie, A. G., Wormwood, K. et al., Mass spectrometry for proteomics-based investigation. Adv. Exp. Med. Biol. 2014, 806, 1-32.
11. Roy, U., Sokolowska, I., Woods, A. G., Darie, C. C., Structural investigation of tumor differentiation factor. Biotechnol. Appl. Biochem. 2012, 59, 445-450.
12. Roy, U., Woods, A. G., Sokolowska, I., Darie, C. C., Structural evaluation and analyses of tumor differentiation factor. Protein J. 2013, 32, 512-518.
13. Sokolowska, I., Woods, A. G., Gawinowicz, M. A., Roy, U., Darie, C. C., Characterization of tumor differentiation factor (TDF) and its receptor (TDF-R). Cell. Mol. Life Sci. 2013, 70, 2835-2848.
14. Sokolowska, I., Woods, A. G., Gawinowicz, M. A., Roy, U., Darie, C. C., Identification of a potential tumor differentiation factor receptor candidate in prostate cancer cells. FEBS J. 2012, 279, 2579-2594.
15. Sokolowska, I., Woods, A. G., Gawinowicz, M. A., Roy, U., Darie, C. C., Identification of potential tumor differentiation factor (TDF) receptor from steroid-responsive and steroid-resistant breast cancer cells. J. Biol. Chem. 2012, 287, 1719-1733.
16. Woods, A. G., Sokolowska, I., Deinhardt, K., Darie, C. C., Investigating a novel protein using mass spectrometry: the example of tumor differentiation factor (TDF). Adv. Exp. Med. Biol. 2014, 806, 509-523.
17. Martins-de-Souza, D., Guest, P. C., Harris, L. W., Vanattou-Saifoudine, N. et al., Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients. Transl. Psychiatry 2012, 2, e87.
18. Kekesi, K. A., Juhasz, G., Simor, A., Gulyassy, P. et al., Altered functional protein networks in the prefrontal cortex and amygdala of victims of suicide. PLoS One 2012, 7, e50532.
19. Guest, P. C., Urday, S., Ma, D., Stelzhammer, V. et al., Proteomic analysis of the maternal protein restriction rat model for schizophrenia: identification of translational changes in hormonal signaling pathways and glutamate neurotransmission. Proteomics 2012, 12, 3580-3589.
20. Woods, A. G., Ngounou Wetie, A. G., Sokolowska, I., Russell, S. et al., Mass spectrometry as a tool for studying autism spectrum disorder. J. Mol. Psychiatry 2013, 1, 6.
21. Scarano, E., Fiorita, A., Picciotti, P. M., Passali, G. C. et al., Proteomics of saliva: personal experience. Acta Otorhinolaryngol Ital. 2010, 30, 125-130.
22. Schulz, B. L., Cooper-White, J., Punyadeera, C. K., Saliva proteome research: current status and future outlook. Crit. Rev. Biotechnol. 2013, 33, 246-259.
23. Shetty, V., Yamaguchi, M., Salivary biosensors for screening trauma-related psychopathology. Oral Maxillofac. Surg. Clin. North Am. 2010, 22, 269-278.
24. Yan, W., Apweiler, R., Balgley, B. M., Boontheung, P. et al., Systematic comparison of the human saliva and plasma proteomes. Proteomics Clin. Appl. 2009, 3, 116-134.
25. Corbett, B. A., Mendoza, S., Abdullah, M., Wegelin, J. A., Levine, S., Cortisol circadian rhythms and response to stress in children with autism. Psychoneuroendocrinology 2006, 31, 59-68.
26. Corbett, B. A., Mendoza, S., Wegelin, J. A., Carmean, V., Levine, S., Variable cortisol circadian rhythms in children with autism and anticipatory stress. J. Psychiatry Neurosci. 2008, 33, 227-234.
27. Feldman, R., Golan, O., Hirschler-Guttenberg, Y., Ostfeld-Etzion, S., Zagoory-Sharon, O., Parent-child interaction and oxytocin production in pre-schoolers with autism spectrum disorder. Br. J. Psychiatry 2014, 205, 107-112.
28. Majewska, M. D., Hill, M., Urbanowicz, E., Rok-Bujko, P. et al., Marked elevation of adrenal steroids, especially androgens, in saliva of prepubertal autistic children. Eur. Child Adolesc. Psychiatry 2014, 23, 485-498.
29. Tecles, F., Fuentes-Rubio, M., Tvarijonaviciute, A., Martinez-Subiela, S. et al., Assessment of stress associated with an oral public speech in veterinary students by salivary biomarkers. J. Vet. Med. Educ. 2014, 41, 37-43.
30. Pfaffe, T., Cooper-White, J., Beyerlein, P., Kostner, K., Punyadeera, C., Diagnostic potential of saliva: current state and future applications. Clin. Chem. 2011, 57, 675-687.
31. Hu, S., Loo, J. A., Wong, D. T., Human saliva proteome analysis and disease biomarker discovery. Expert Rev. Proteomics 2007, 4, 531-538.
32. St John, M. A., Li, Y., Zhou, X., Denny, P. et al., Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2004, 130, 929-935.
33. Barr, T. L., VanGilder, R., Rellick, S., Brooks, S. D. et al., A genomic profile of the immune response to stroke with implications for stroke recovery. Biol. Res. Nurs. 2014, pii: 1099800414546492.
34. Castagnola, M., Messana, I., Inzitari, R., Fanali, C. et al., Hypo-phosphorylation of salivary peptidome as a clue to the molecular pathogenesis of autism spectrum disorders. J. Proteome Res. 2008, 7, 5327-5332.
35. Bermejo-Pareja, F., Antequera, D., Vargas, T., Molina, J. A., Carro, E., Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study. BMC Neurol. 2010, 10, 108.
36. Devic, I., Hwang, H., Edgar, J. S., Izutsu, K. et al., Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011, 134, e178-e178.
37. Nam, J. W., Chung, J. W., Kho, H. S., Chung, S. C., Kim, Y. K., Nerve growth factor concentration in human saliva. Oral Dis. 2007, 13, 187-192.
38. Oh, Y. S., Turner, R. J., Effect of gamma-secretase inhibitors on muscarinic receptor-mediated calcium signaling in human salivary epithelial cells. Am. J. Physiol. Cell Physiol. 2006, 291, C76-C82.
39. Shi, M., Sui, Y. T., Peskind, E. R., Li, G. et al., Salivary tau species are potential biomarkers of Alzheimer's disease. J. Alzheimers Dis. 2011, 27, 299-305.
40. Collins, S. M., Surette, M., Bercik, P., The interplay between the intestinal microbiota and the brain. Nat. Rev. Microbiol. 2012, 10, 735-742.
41. Dallner, C., Woods, A. G., Deller, T., Kirsch, M., Hofmann, H. D., CNTF and CNTF receptor alpha are constitutively expressed by astrocytes in the mouse brain. Glia 2002, 37, 374-378.
42. Woods, A. G., Guthrie, K. M., Kurlawalla, M. A., Gall, C. M., Deafferentation-induced increases in hippocampal insulin-like growth factor-1 messenger RNA expression are severely attenuated in middle aged and aged rats. Neuroscience 1998, 83, 663-668.
43. Blumberg, S. J., Bramlett, M. D., Kogan, M. D., Schieve, L. A. et al. Changes in Prevalence of Parent-reported Autism Spectrum Disorder in School-aged U.S. Children: 2007 to 2011-2012. Centers for Disease Control and Prevention, National Center for Health Statistics, Hyattsville, MD 2013.
44. Deng, Y. H., Wang, H., Zhang, H. S., Determination of amino acid neurotransmitters in human cerebrospinal fluid and saliva by capillary electrophoresis with laser-induced fluorescence detection. J. Sep. Sci. 2008, 31, 3088-3097.
45. Perry, M., Li, Q., Kennedy, R. T., Review of recent advances in analytical techniques for the determination of neurotransmitters. Anal. Chim. Acta 2009, 653, 1-22.
46. Woods, A. G., Use a saliva test to ID neurodegenerative disease? Psychiatic Times 2014, p. 1.
47. Shi, M., Zabetian, C. P., Hancock, A. M., Ginghina, C. et al., Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci. Lett. 2010, 480, 78-82.
48. Blennow, K., Hampel, H., CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003, 2, 605-613.
49. Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L. et al., Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9, 1118-1127.
50. Dubois, B., Feldman, H. H., Jacova, C., Dekosky, S. T. et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6, 734-746.
51. Duits, F. H., Prins, N. D., Lemstra, A. W., Pijnenburg, Y. A. et al., Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. Alzheimers Dement. 2014, pii: S1552-5260(14)02461-3.
52. Hong, Z., Shi, M., Chung, K. A., Quinn, J. F. et al., DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133, 713-726.
53. Devic, I., Hwang, H., Edgar, J. S., Izutsu, K. et al., Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011, 134, e178.
54. Wingate, M., Kirby, R. S., Pettygrove, S., Cunniff, C. et al., Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill. Summ. 2014, 28, 1-21.
55. Quaak, I., Brouns, M. R., vande Bor, M., The dynamics of autism spectrum disorders: how neurotoxic compounds and neurotransmitters interact. Int. J. Environ. Res. Public Health 2013, 10, 3384-3408.
56. laMarca, G., Mass spectrometry in clinical chemistry: the case of newborn screening. J. Pharmaceut. Biomed. Anal. 2014, 101, 174-182.
57. Wilcken, B., Screening for disease in the newborn: the evidence base for blood-spot screening. Pathology 2012, 44, 73-79.
58. Ngounou Wetie, A. G., Wormwood, K., Thome, J., Dudley, E. et al., A pilot proteomic study of protein markers in autism spectrum disorder. Electrophoresis 2014, 35, 2046-2054.
59. Momeni, N., Brudin, L., Behnia, F., Nordstrom, B. et al., High complement factor I activity in the plasma of children with autism spectrum disorders. Autism Res. Treat. 2012, 2012, 868576.
60. Momeni, N., Bergquist, J., Brudin, L., Behnia, F. et al., A novel blood-based biomarker for detection of autism spectrum disorders. Transl. Psychiatry 2012, 2, e91.
61. Corbett, B. A., Kantor, A. B., Schulman, H., Walker, W. L. et al., A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol. Psychiatry 2007, 12, 292-306.
62. Ngounou Wetie, A. G., Wormwood, K., Russell, S., Ryan, J. P. et al., A pilot proteomic analysis of salivary biomarkers in autism spectrum disorder. Autism Res. 2015. doi: 10.1002/aur.1450. [Epub ahead of print]
63. Cuenca, A. G., Wynn, J. L., Moldawer, L. L., Levy, O., Role of innate immunity in neonatal infection. Am. J. Perinatol. 2013, 30, 105-112.
64. D'Acquisto, F., On the adaptive nature of annexin-A1. Curr. Opin. Pharmacol. 2009, 9, 521-528.
65. Hamilos, D. L., Host-microbial interactions in patients with chronic rhinosinusitis. J. Allergy Clin. Immunol. 2013, 131, 1263-1264, 1264.e1261-1266.
66. Liu, Y., Bartlett, J. A., Di, M. E., Bomberger, J. M. et al., SPLUNC1/BPIFA1 contributes to pulmonary host defense against Klebsiella pneumoniae respiratory infection. Am. J. Pathol. 2013, 182, 1519-1531.
67. Zerbo, O., Yoshida, C., Grether, J. K., vande Water, J. et al., Neonatal cytokines and chemokines and risk of autism spectrum disorder: the Early Markers for Autism (EMA) study: a case-control study. J. Neuroinflamm. 2014, 11, 113.
68. Saxena, V., Ramdas, S., Ochoa, C. R., Wallace, D. et al., Structural, genetic, and functional signatures of disordered neuro-immunological development in autism spectrum disorder. PLoS One 2012, 7, e48835.
69. Masi, A., Quintana, D. S., Glozier, N., Lloyd, A. R. et al., Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol. Psychiatry 2014. doi: 10.1038/mp.2014.59.
70. Gesundheit, B., Rosenzweig, J. P., Naor, D., Lerer, B. et al., Immunological and autoimmune considerations of autism spectrum disorders. J. Autoimmun. 2013, 44, 1-7.
71. Samsam, M., Ahangari, R., Naser, S. A., Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance. World J. Gastroenterol. 2014, 20, 9942-9951.
72. Li, S., Iakoucheva, L. M., Mooney, S. D., Radivojac, P., Loss of post-translational modification sites in disease. Pac. Symp. Biocomput. 2010, 337-347.
73. Woods, A. G., Iosifescu, D. V., Darie, C. C., Biomarkers in major depressive disorder: the role of mass spectrometry. Adv. Exp. Med. Biol. 2014, 806, 545-560.
74. Filiou, M. D., Turck, C. W., Martins-de-Souza, D., Quantitative proteomics for investigating psychiatric disorders. Proteomics Clin. Appl. 2011, 5, 38-49.
75. Martins-de-Souza, D., Proteomics, metabolomics, and protein interactomics in the characterization of the molecular features of major depressive disorder. Dialogues Clin. Neurosci. 2014, 16, 63-73.
76. Stelzhammer, V., Haenisch, F., Chan, M. K., Cooper, J. D. et al., Proteomic changes in serum of first onset, antidepressant drug-naive major depression patients. Int. J. Neuropsychopharmacol. 2014, 17, 1599-1608.
77. Ninan, P. T., Shelton, R. C., Bao, W., Guico-Pabia, C. J., BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48, 86-91.
78. To, S. E., Zepf, R. A., Woods, A. G., The symptoms, neurobiology, and current pharmacological treatment of depression. J. Neurosci. Nurs. 2005, 37, 102-107.
79. Egami, M., Imamura, Y., Nabeta, H., Mizoguchi, Y., Yamada, S., Saliva levels of 3-methoxy-4 hydroxyphenylglycol and clinical efficacy of mirtazapine or selective serotonin reuptake inhibitors in patients with major depression. Hum Psychopharmacol. 2013. doi: 10.1002/hup.2273.
80. Bazzichi, L., Ciregia, F., Giusti, L., Baldini, C. et al., Detection of potential markers of primary fibromyalgia syndrome in human saliva. Proteomics Clin. Appl. 2009, 3, 1296-1304.
81. Cryan, J. F., Dinan, T. G., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 2012, 13, 701-712.
82. Diamond, B., Huerta, P. T., Tracey, K., Volpe, B. T., It takes guts to grow a brain: increasing evidence of the important role of the intestinal microflora in neuro- and immune-modulatory functions during development and adulthood. BioEssays 2011, 33, 588-591.
83. Cockburn, A. F., Dehlin, J. M., Ngan, T., Crout, R. et al., High throughput DNA sequencing to detect differences in the subgingival plaque microbiome in elderly subjects with and without dementia. Investig. Genet. 2012, 3, 19.
84. Dominy, S. S., Brown, J. N., Ryder, M. I., Gritsenko, M. et al., Proteomic analysis of saliva in HIV-positive heroin addicts reveals proteins correlated with cognition. PLoS One 2014, 9, e89366.
85. Dickinson, D., Ramsey, M. E., Gold, J. M., Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch. Gen. Psychiatry 2007, 64, 532-542.